175 related articles for article (PubMed ID: 32383226)
1. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China.
Xu Y; Wang T; Yang Z; Lin H; Shen P; Zhan S
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):635-643. PubMed ID: 32383226
[TBL] [Abstract][Full Text] [Related]
2. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
[TBL] [Abstract][Full Text] [Related]
3. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
[TBL] [Abstract][Full Text] [Related]
4. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
He S; Qian X; Chen Y; Shen X; Zhang B; Chen X; Xu X; Li G
J Diabetes Res; 2021; 2021():5534387. PubMed ID: 34222493
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
9. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
[TBL] [Abstract][Full Text] [Related]
11. Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.
Islam N; Reynier P; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Jun; 25(6):1523-1533. PubMed ID: 36722703
[TBL] [Abstract][Full Text] [Related]
12. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.
Roumie CL; Min JY; D'Agostino McGowan L; Presley C; Grijalva CG; Hackstadt AJ; Hung AM; Greevy RA; Elasy T; Griffin MR
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28424149
[TBL] [Abstract][Full Text] [Related]
13. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study.
Tseng YH; Tsan YT; Chan WC; Sheu WH; Chen PC
Diabetes Care; 2015 Nov; 38(11):2068-74. PubMed ID: 26307605
[TBL] [Abstract][Full Text] [Related]
14. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
[TBL] [Abstract][Full Text] [Related]
15. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
16. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
17. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
19. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
20. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
